These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 31090187)

  • 1. Increased risk of opportunistic infection in early rheumatoid arthritis.
    Kim H; Cho SK; Lee J; Bae SC; Sung YK
    Int J Rheum Dis; 2019 Jul; 22(7):1239-1246. PubMed ID: 31090187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No increased risk of herpes zoster in TNF inhibitor and non-TNF inhibitor users with rheumatoid arthritis: epidemiological study using the Japanese health insurance database.
    Sakai R; Kasai S; Hirano F; Harada S; Kihara M; Yokoyama W; Tsutsumino M; Nagasaka K; Koike R; Yamanaka H; Miyasaka N; Harigai M
    Int J Rheum Dis; 2018 Sep; 21(9):1670-1677. PubMed ID: 29667330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy.
    Yun H; Xie F; Delzell E; Chen L; Levitan EB; Lewis JD; Saag KG; Beukelman T; Winthrop K; Baddley JW; Curtis JR
    Arthritis Care Res (Hoboken); 2015 May; 67(5):731-6. PubMed ID: 25201241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.
    Baddley JW; Winthrop KL; Chen L; Liu L; Grijalva CG; Delzell E; Beukelman T; Patkar NM; Xie F; Saag KG; Herrinton LJ; Solomon DH; Lewis JD; Curtis JR
    Ann Rheum Dis; 2014 Nov; 73(11):1942-8. PubMed ID: 23852763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs.
    Pappas DA; Hooper MM; Kremer JM; Reed G; Shan Y; Wenkert D; Greenberg JD; Curtis JR
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1671-8. PubMed ID: 26018115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant Associations of Neurological Complications of Herpes Zoster With Stroke in Rheumatoid Arthritis Patients.
    Liao TL; Lin CH; Chen HH; Chen YM; Lin CC; Chen DY
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom.
    Smitten AL; Choi HK; Hochberg MC; Suissa S; Simon TA; Testa MA; Chan KA
    Arthritis Rheum; 2007 Dec; 57(8):1431-8. PubMed ID: 18050184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.
    Winthrop KL; Baddley JW; Chen L; Liu L; Grijalva CG; Delzell E; Beukelman T; Patkar NM; Xie F; Saag KG; Herrinton LJ; Solomon DH; Lewis JD; Curtis JR
    JAMA; 2013 Mar; 309(9):887-95. PubMed ID: 23462785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.
    Winthrop KL; Park SH; Gul A; Cardiel MH; Gomez-Reino JJ; Tanaka Y; Kwok K; Lukic T; Mortensen E; Ponce de Leon D; Riese R; Valdez H
    Ann Rheum Dis; 2016 Jun; 75(6):1133-8. PubMed ID: 26318385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry.
    Salmon JH; Gottenberg JE; Ravaud P; Cantagrel A; Combe B; Flipo RM; Schaeverbeke T; Houvenagel E; Gaudin P; Loeuille D; Rist S; Dougados M; Sibilia J; Le Loët X; Meyer O; Solau-Gervais E; Marcelli C; Bardin T; Pane I; Baron G; Perrodeau E; Mariette X;
    Ann Rheum Dis; 2016 Jun; 75(6):1108-13. PubMed ID: 26048170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of disease duration and socioeconomic factors on the prevalence of infection and hospitalization in rheumatoid arthritis: KRAC study.
    Chandrashekara S; Shobha V; Dharmanand BG; Jois R; Kumar S; Mahendranath KM; Haridas V; Prasad S; Singh Y; Daware MA; Swamy A; Subramanian R; Somashekar SA; Shanthappa AM; Anupama KR
    Int J Rheum Dis; 2019 Jul; 22(7):1216-1225. PubMed ID: 30977300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Rutherford AI; Patarata E; Subesinghe S; Hyrich KL; Galloway JB
    Rheumatology (Oxford); 2018 Jun; 57(6):997-1001. PubMed ID: 29529307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study.
    Choi SR; Shin A; Ha YJ; Lee YJ; Lee EB; Kang EH
    Arthritis Res Ther; 2023 Jul; 25(1):129. PubMed ID: 37495973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitors.
    Segan J; Staples MP; March L; Lassere M; Chakravarty EF; Buchbinder R
    Intern Med J; 2015 Mar; 45(3):310-8. PubMed ID: 25565419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan.
    Chiu YM; Lang HC; Lin HY; Yang MT; Fang CH; Yang YW; Schabert VF; Tang B
    Int J Rheum Dis; 2014 Dec; 17 Suppl 3():9-19. PubMed ID: 25496045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders.
    Wolfe F; Michaud K; Chakravarty EF
    Rheumatology (Oxford); 2006 Nov; 45(11):1370-5. PubMed ID: 17003175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.
    Simon TA; Askling J; Lacaille D; Franklin J; Wolfe F; Covucci A; Suissa S; Hochberg MC;
    Arthritis Res Ther; 2010; 12(2):R67. PubMed ID: 20398273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Medications and Herpes Zoster in Japanese Patients with Rheumatoid Arthritis: A 5-year Prospective Cohort Study.
    Harada S; Sakai R; Hirano F; Miyasaka N; Harigai M;
    J Rheumatol; 2017 Jul; 44(7):988-995. PubMed ID: 28412701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
    Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.
    Simon TA; Boers M; Hochberg M; Baker N; Skovron ML; Ray N; Singhal S; Suissa S; Gomez-Caminero A
    Arthritis Res Ther; 2019 Nov; 21(1):228. PubMed ID: 31703717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.